Title : A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).

Pub. Date : 2021

PMID : 33613698






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Methods: Herein, we introduce our phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected NSCLC with EGFR mutation. Cisplatin epidermal growth factor receptor Homo sapiens